Trials / Unknown
UnknownNCT02696525
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 145 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
Detailed description
Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients. We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
Conditions
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2016-03-02
- Last updated
- 2018-05-21
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02696525. Inclusion in this directory is not an endorsement.